240 likes | 371 Views
Clinical Core Ron Petersen Paul Aisen Mike Donohue. ICAD July 10, 2010. ISAB requests. Impact of medications on decline AChEI Antihypertensives NSAIDs [PPAR gamma agonists (too few)]. AChEI v. no AChEI. MCI ADAS CDR-SB Hipp volume. BP meds v. no BP meds. MCI ADAS Hipp vol NL
E N D
Clinical Core Ron Petersen Paul Aisen Mike Donohue ICAD July 10, 2010
ISAB requests • Impact of medications on decline • AChEI • Antihypertensives • NSAIDs • [PPAR gamma agonists (too few)]
AChEI v. no AChEI • MCI • ADAS • CDR-SB • Hipp volume
BP meds v. no BP meds • MCI • ADAS • Hipp vol • NL • Hipp vol
NSAIDs v. no NSAIDs • MCI • ADAS • Hipp vol • NL • Hipp vol
Summary: key points • AChEI therapy is a powerful marker of increased decline in MCI • Anti-hypertensives and NSAIDs do not have much effect on progression in any group • The predictors of conversion to MCI from NL are APOE and ADAScog13
Preview of Sunday symposium • Predictors of conversion from MCI to AD in multiple studies • Pieter Jelle Visser